Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine

Vaccine

Volumn 27, Issue 41, 2009, Pages 5612-5619

  Rowhani Rahbar, Ali ^a   Mao, Constance ^b   Hughes, James P ^a   Alvarez, Frances B ^c   Bryan, Janine T ^c   Hawes, Stephen E ^a   Weiss, Noel S ^a   Koutsky, Laura A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Human papillomavirus type 16; Prophylactic vaccines

Indexed keywords

PLACEBO; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOASSAY; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; PROPHYLAXIS; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIRUS LIKE AGENT;

ADOLESCENT; CAPSID PROTEINS; CERVIX UTERI; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PLACEBOS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINES, VIROSOME; YOUNG ADULT;

EID: 68949170683     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.027     Document Type: Article

References (44)

1. Bosch F.X., and de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
3. Koutsky L.A., and Harper D.M. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 24 Suppl. 3 (2006) 114-121
4. La Torre G., de Waure C., Chiaradia G., Mannocci A., and Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 25 50 (2007) 8352-8358
5. Rambout L., Hopkins L., Hutton B., and Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177 5 (2007) 469-479
6. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
7. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
8. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
9. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
10. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
11. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
12. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (2007) 1915-1927
13. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861-8.
14. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
15. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
16. Perez G., Lazcano-Ponce E., Hernandez-Avila M., Garcia P.J., Munoz N., Villa L.L., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 122 6 (2008) 1311-1318
17. Gall S., Teixeira J., Wheeler C., Naud P., Harper D.M., Franco E., et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. American association for cancer research annual meeting. Los Angeles, CA, USA, April 14-18 (2007)
18. Food and Drug Administration. Available at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html.
19. Kim J.J., Kobus K.E., Diaz M., O'Shea M., Van Minh H., and Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 26 32 (2008) 4015-4024
20. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 8 (2004) 604-615
21. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., and Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106 6 (2003) 896-904
22. Goldie S.J. Health economics and cervical cancer prevention: a global perspective. Virus Res 89 2 (2002) 301-309
23. Garnett G.P., Kim J.J., French K., and Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl. 3 (2006) 178-186
24. Diaz M., Kim J.J., Albero G., de Sanjose S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 99 2 (2008) 230-238
25. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (2006) e138
26. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
27. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (2003) 37-48
28. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 11 (2004) 1915-1923
29. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 1 (2007) 28-41
30. Brisson M., Van de Velde N., De Wals P., and Boily M.C. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 177 5 (2007) 464-468
31. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 29 (2007) 5399-5408
32. Van de Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165 7 (2007) 762-775
33. Jacob M., Bradley J., and Barone M.A. Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs?. Sex Transm Dis 32 10 (2005) 635-640
34. People Search. Available at: http://www.peoplesearch.com/.
35. Accurint. Available at: http://www.accurint.com/.
36. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
37. Hildesheim A., Herrero R., Wacholder S., Rodriguez A.C., Solomon D., Bratti M.C., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 7 (2007) 743-753
38. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 24 27/28 (2006) 5571-5583
39. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A.R., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25 21 (2007) 4324-4333
40. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 26 (2007) 4931-4939
41. Hudgens M.G., Hoering A., and Self S.G. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med 22 14 (2003) 2281-2298
42. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (2003) 63-73
43. Lehtinen M., Apter D., Dubin G., Kosunen E., Isaksson R., Korpivaara E.L., et al. Enrolment of 22.000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 17 8 (2006) 517-521
44. Lehtinen M., Idanpaan-Heikkila I., Lunnas T., Palmroth J., Barr E., Cacciatore R., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 17 4 (2006) 237-246